Introduction: Katrina A. Bollinger is a prominent inventor based in Murfreesboro, Tennessee, who has made significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of six patents to her name, Bollinger's work primarily focuses on the discovery and development of positive allosteric modulators aimed at treating neurological and psychiatric disorders.

Latest Patents: Among her latest inventions are two noteworthy patents that highlight her innovative approach in drug development. The first patent discusses positive allosteric modulators of the muscarinic acetylcholine receptor M. This groundbreaking research outlines pharmaceutical compositions that include these compounds and various methods for using them in the treatment of neurological and psychiatric disorders.

Her second patent further explores the realm of muscarinic acetylcholine receptor M4 with the disclosure of pyrido[3',2' : 4,5]thieno[3,2-d]pyrimidine and pyrimido[4',5' : 4,5]thieno[2,3-c]pyridazine compounds. These compounds are described as promising candidates for positive allosteric modulation of the M receptor, with methodologies for creating these compounds and utilizing them in pharmaceutical compositions.

Career Highlights: Katrina A. Bollinger is currently associated with Vanderbilt University, where her research continues to push the boundaries of pharmacotherapy. Throughout her career, she has demonstrated an unparalleled commitment to expanding our understanding of receptor function and its implications for treatment strategies for complex health issues.

Collaborations: Working alongside esteemed colleagues such as P. Jeffrey Conn and Craig William Lindsley, Bollinger has fostered a collaborative environment that encourages innovative thinking and problem-solving. Her ability to work effectively within a team has led to the advancement of research that has the potential to make significant impacts in the medical field.

Conclusion: Katrina A. Bollinger stands out as a remarkable inventor whose work is integral to advancing therapeutic options for neurological and psychiatric disorders. With her innovative drugs and collaborative spirit, she continues to contribute valuable insights and discoveries that may one day transform patient care in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.